# Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

> **NCT01727713** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 110 (actual)

## Conditions studied

- Tourette's Disorder
- Tic Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01727713
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727713, "Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01727713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*